Company Announcements
Director/PDMR Shareholding
Related Companies
By LSE RNS
28 March 2017 16:00 BST
TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announces that, on 28 March 2017, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) and of American Depositary Shares (ADSs) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP). Two ADSs are equivalent to one Ordinary Share.
The AZDBP award was granted on 28 March 2014, following the deferral of a portion of each PDMR's annual bonus paid in respect of 2013 performance into Ordinary Shares or ADSs, and vested on completion of the three-year holding period.
The AZPSP award was granted on 28 March 2014. Following the application of performance measures specified at the time of grant, 92% of the AZPSP vested and the remaining unvested part immediately and irrevocably lapsed.
Following the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares and ADSs changed as detailed in the table below:
|
PDMR |
Ordinary Shares acquired under the AZDBP |
ADSs acquired under the AZDBP |
Ordinary Shares acquired under the AZPSP |
ADSs acquired under the AZPSP |
|
Pascal Soriot |
14,209 |
|
101,584 |
|
|
Marc Dunoyer |
1,419 |
|
25,478 |
|
|
Mark Mallon |
|
620 |
|
22,000 |
For tax purposes, the fair market value of an Ordinary Share at vest was 4974.5 pence and the fair market value of an ADS at vest was $31.80, being the relevant closing prices on the last trading day preceding the vesting day.
Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
|
Media Enquiries
|
|
|
|
Esra Erkal-Paler |
UK/Global |
+44 203 749 5638 |
|
Vanessa Rhodes
|
UK/Global
|
+44 203 749 5736
|
|
Karen Birmingham
|
UK/Global
|
+44 203 749 5634
|
|
Rob Skelding
|
UK/Global
|
+44 203 749 5821
|
|
Jacob Lund
|
Sweden
|
+46 8 553 260 20
|
|
Michele Meixell
|
US
|
+1 302 885 2677
|
|
Investor Relations |
|
|
|
Thomas Kudsk Larsen
|
|
+44 203 749 5712
|
|
Craig Marks
|
Finance, Fixed Income, M&A
|
+44 7881 615 764
|
|
Henry Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Mitchell Chan
|
Oncology
|
+1 240 477 3771
|
|
Lindsey Trickett
|
Cardiovascular & Metabolic Diseases
|
+1 240 543 7970
|
|
Nick Stone
|
Respiratory
|
+44 203 749 5716
|
|
Christer Gruvris |
Autoimmunity, Neuroscience & Infection |
+44 203 749 5711 |
|
US toll free |
|
+1 866 381 7277 |
Adrian Kemp
Company Secretary, AstraZeneca PLC
|
1
|
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a)
|
Name |
Pascal Soriot |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Executive Officer |
||||
|
b)
|
Initial notification /Amendment |
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
Name |
AstraZeneca PLC |
||||
|
b)
|
LEI |
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4i
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code |
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
||||
|
b)
|
Nature of the transaction
|
Acquisition of ordinary shares pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration. |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume - Price |
Not applicable - single transaction
|
||||
|
e)
|
Date of the transaction
|
28 March 2017 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a)
|
Name |
Marc Dunoyer |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Financial Officer |
||||
|
b)
|
Initial notification /Amendment |
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
Name |
AstraZeneca PLC |
||||
|
b)
|
LEI |
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4i
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code |
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
||||
|
b)
|
Nature of the transaction
|
Acquisition of ordinary shares pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration. |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume - Price |
Not applicable - single transaction
|
||||
|
e)
|
Date of the transaction
|
28 March 2017 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a)
|
Name |
Mark Mallon |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Person Discharging Managerial Responsibilities |
||||
|
b)
|
Initial notification /Amendment |
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
Name |
AstraZeneca PLC |
||||
|
b)
|
LEI |
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4i
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108 |
||||
|
b)
|
Nature of the transaction
|
Acquisition of ADSs pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration. |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume - Price
|
Not applicable - single transaction |
||||
|
e)
|
Date of the transaction
|
28 March 2017 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||
This information is provided by RNS
You are here: news > regulatory news
10 Lower Thames St,
London EC3R 6EN